Gabelli Funds LLC Acquires Shares of 187,500 Niagen Bioscience, Inc. $NAGE

Gabelli Funds LLC acquired a new stake in shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 187,500 shares of the company’s stock, valued at approximately $1,749,000.

Several other large investors also recently modified their holdings of the business. Vanguard Group Inc. purchased a new position in Niagen Bioscience during the 3rd quarter valued at about $37,522,000. Dimensional Fund Advisors LP purchased a new stake in Niagen Bioscience in the 3rd quarter worth approximately $6,773,000. JPMorgan Chase & Co. bought a new stake in shares of Niagen Bioscience in the 3rd quarter worth approximately $3,678,000. Victory Capital Management Inc. bought a new stake in shares of Niagen Bioscience in the 3rd quarter worth approximately $3,536,000. Finally, Hillsdale Investment Management Inc. purchased a new position in shares of Niagen Bioscience during the third quarter valued at approximately $2,988,000. 15.41% of the stock is owned by institutional investors.

Niagen Bioscience Stock Performance

Shares of NASDAQ:NAGE opened at $4.89 on Thursday. Niagen Bioscience, Inc. has a 52-week low of $4.72 and a 52-week high of $14.69. The firm has a market capitalization of $391.59 million, a P/E ratio of 24.45 and a beta of 2.11. The stock has a 50 day moving average price of $5.66 and a 200-day moving average price of $7.02.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on NAGE. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Canaccord Genuity Group decreased their price objective on shares of Niagen Bioscience from $14.00 to $13.00 and set a “buy” rating for the company in a report on Thursday, March 5th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Niagen Bioscience Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.